Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 5:00 AM ET

Date/Time Source News Release
02/10/2025 07:00 AM EST GlobeNewswire RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties
05/29/2024 08:15 AM EDT GlobeNewswire RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
03/20/2024 08:30 AM EDT GlobeNewswire RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
02/13/2024 08:30 AM EST GlobeNewswire RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
01/22/2024 08:30 AM EST GlobeNewswire RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
01/04/2024 08:45 AM EST GlobeNewswire RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient
12/11/2023 08:30 AM EST GlobeNewswire RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development
10/12/2023 08:45 AM EDT GlobeNewswire RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services
08/09/2023 08:50 AM EDT GlobeNewswire RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company
05/24/2023 08:30 AM EDT GlobeNewswire ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs
Page

Additional News

As of June 4, 2025 • 5:00 AM ET

Date/Time Source News Release
01/03/2025 06:00 AM EST US Earnings Reports Expected US Company Earnings on Friday, January 3rd, 2025
01/03/2025 04:31 AM EST US Earnings Reports Expected earnings - RespireRx Pharmaceuticals Inc
12/27/2024 06:00 AM EST US Earnings Reports Expected US Company Earnings on Friday, December 27th, 2024
12/27/2024 04:31 AM EST US Earnings Reports Expected earnings - RespireRx Pharmaceuticals Inc
12/20/2024 06:00 AM EST US Earnings Reports Expected US Company Earnings on Friday, December 20th, 2024
12/20/2024 04:31 AM EST US Earnings Reports Expected earnings - RespireRx Pharmaceuticals Inc
12/13/2024 06:00 AM EST US Earnings Reports Expected US Company Earnings on Friday, December 13th, 2024
12/13/2024 04:31 AM EST US Earnings Reports Expected earnings - RespireRx Pharmaceuticals Inc
12/06/2024 06:00 AM EST US Earnings Reports Expected US Company Earnings on Friday, December 6th, 2024
12/06/2024 04:31 AM EST US Earnings Reports Expected earnings - RespireRx Pharmaceuticals Inc
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.